← All trials
NCT04448379
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Jun 30, 2022
- First posted
- Jun 25, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai JMT-Bio Inc.Lead sponsor
- Shijiazhuang Pharma Group (CSPC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.